Medicare Rx Plan Price Reviews By CMS Are “Appropriate,” MedPAC Says
Executive Summary
The Centers for Medicare & Medicaid Services' proposal to review Medicare prescription drug prices when negotiating plan bids is "appropriate," the Medicare Payment Advisory Commission said
You may also be interested in...
Medicare Rx “Fallback” Plans Ensured Small Role Under CMS Rule
Entities administering a Medicare prescription drug "fallback" plan in a single U.S. region will be prohibited from bidding as stand-alone PDPs anywhere nationwide during the three-year contract term, CMS' proposed regulation says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials